Eisai (OTCPK:ESALF), which is partnered with Biogen (NASDAQ:BIIB) on the Alzheimer's disease treatment Leqembi (lecanemab), expects a major increase in revenue for the therapy in its fiscal year 2024,...
Source LinkEisai (OTCPK:ESALF), which is partnered with Biogen (NASDAQ:BIIB) on the Alzheimer's disease treatment Leqembi (lecanemab), expects a major increase in revenue for the therapy in its fiscal year 2024,...
Source Link
Comments